The U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for Aqvesme (mitapivat) on 2025-12-23. This action, categorized as an efficacy supplement (NDA 216196 S-3), indicates an update or expansion related to the drug's demonstrated effectiveness.
Background
Aqvesme, also known by its generic name mitapivat, is a medication developed by AGIOS PHARMS INC. The drug is also referred to as Pyrukynd. As this is a supplemental approval, Aqvesme has an existing marketing authorization from the FDA. Supplemental applications are filed to propose changes to an approved application, which can include new indications, new dosing regimens, or changes to the drug's label based on new efficacy data.
What this means
The FDA's supplemental approval for Aqvesme (mitapivat) related to efficacy signifies an important development for the drug's therapeutic profile. While the specific details of the expanded indication, patient population, or other efficacy-related updates are not provided in this summary, such approvals typically mean that new clinical data has demonstrated additional benefits or confirmed efficacy in a new context. This could lead to updated prescribing information for clinicians, potentially expanding the patient population eligible for treatment with Aqvesme or refining its use in existing indications. This type of approval is a standard process for drugs as new research emerges, allowing their labels to reflect the most current understanding of their benefits.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on 2025-12-23. The details are publicly available on the accessdata.fda.gov website, under New Drug Application (NDA) 216196 and supplemental application S-3.